Netarsudil Suppliers & Bulk Manufacturers

Available Forms: Eye Drops

Available Strengths: 0.02%

Reference Brands: Rhopressa (USA)

Category: Opthalmology

Product Description:

Netarsudil ophthalmic solution (0.02%), marketed under the brand name Rhopressa, is an FDA-approved therapy indicated for the treatment of glaucoma and ocular hypertension. Approved in December 2017, it belongs to the class of Rho-kinase (ROCK) inhibitors and is designed to lower elevated intraocular pressure (IOP), a major risk factor for optic nerve damage and progressive vision loss in primary open-angle glaucoma.

Netarsudil works by increasing aqueous humor outflow through the trabecular meshwork and reducing episcleral venous pressure, effectively decreasing IOP. This targeted mechanism helps prevent optic nerve fiber damage and minimizes the risk of permanent visual field loss. The medication is administered as a 0.02% ophthalmic solution, typically once daily, providing convenient and effective management of eye pressure for patients.

Rhopressa therapy emphasizes the importance of adherence to prescribed dosing, regular ophthalmologic follow-up, and careful monitoring of intraocular pressure. It has been shown to be generally well-tolerated, with a safety profile consistent with topical ocular therapies. By combining efficacy, ease of use, and a targeted mechanism, netarsudil represents a significant advancement in the management of glaucoma and ocular hypertension, supporting long-term visual preservation and improved patient outcomes.